(COO) The Cooper Companies - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2166484020
COO: Lenses, Devices, Contraceptives, Equipment, Services, Products
The Cooper Companies, Inc. (NASDAQ:COO) stands out as a leader in the medical device industry, with a dual focus that offers both stability and growth potential. The companys two main segments, CooperVision and CooperSurgical, cater to distinct yet complementary markets, providing a balanced portfolio for investors.
CooperVision specializes in contact lenses, addressing a range of vision correction needs including astigmatism, presbyopia, and myopia. Their product line includes both corrective and specialty lenses, serving diverse markets globally, particularly in emerging regions where demand for vision correction is on the rise. This segments global reach and focus on innovation position it well for sustained growth.
CooperSurgical, on the other hand, is dedicated to womens and family healthcare, offering a broad array of products and services. This includes fertility solutions, contraceptives, and cryostorage services. The growing awareness and demand for reproductive health services underscore the potential for expansion in this segment.
Financially, the company boasts a market cap of approximately $18.7 billion, reflecting its established presence. The P/E ratio of 47.8 indicates high expectations for future growth, while the forward P/E of 23.53 suggests a more moderate growth trajectory. The P/B ratio of 2.31 highlights the markets confidence in the companys intangible assets and growth prospects. The P/S ratio of 4.91 underscores strong revenue generation relative to its market cap.
Investors may find appeal in the companys diversification across two stable industries, reducing vulnerability to sector-specific downturns. While the valuation multiples are high, the companys leadership positions and growth drivers in emerging markets and healthcare may justify this premium, offering a compelling case for those seeking exposure to the medical device sector.
Additional Sources for COO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
COO Stock Overview
Market Cap in USD | 18,192m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 1983-12-30 |
COO Stock Ratings
Growth 5y | 15.9% |
Fundamental | 23.2% |
Dividend | 5.68% |
Rel. Strength Industry | -20.7 |
Analysts | 4/5 |
Fair Price Momentum | 69.06 USD |
Fair Price DCF | 32.76 USD |
COO Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 60.6% |
COO Growth Ratios
Growth Correlation 3m | -53% |
Growth Correlation 12m | 0.6% |
Growth Correlation 5y | 22.8% |
CAGR 5y | 4.61% |
CAGR/Max DD 5y | 0.10 |
Sharpe Ratio 12m | -1.18 |
Alpha | -27.75 |
Beta | 0.55 |
Volatility | 42.75% |
Current Volume | 2436.7k |
Average Volume 20d | 2061.5k |
As of March 16, 2025, the stock is trading at USD 81.22 with a total of 2,436,702 shares traded.
Over the past week, the price has changed by -4.45%, over one month by -7.81%, over three months by -13.58% and over the past year by -19.98%.
Neither. Based on ValueRay Fundamental Analyses, The Cooper Companies is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.16 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COO as of March 2025 is 69.06. This means that COO is currently overvalued and has a potential downside of -14.97%.
The Cooper Companies has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy COO.
- Strong Buy: 9
- Buy: 2
- Hold: 7
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, COO The Cooper Companies will be worth about 75.1 in March 2026. The stock is currently trading at 81.22. This means that the stock has a potential downside of -7.52%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 111.2 | 36.9% |
Analysts Target Price | 112 | 37.9% |
ValueRay Target Price | 75.1 | -7.5% |